Aldeyra Therapeutics has been hit by a securities fraud lawsuit alleging that it covered up inconsistencies in clinical trial data for its eye treatment candidate, reproxalap. Investors who purchased shares during the specified period and experienced losses may now seek to lead the class action.

Boston Scientific (BSX) shareholders could soon take the lead in a potential securities fraud lawsuit. A recent press release out of New York highlighted the opportunity for investors to spearhead legal action against the global medical device company.

Quanex Building Products Corporation’s latest financials have prompted a securities fraud lawsuit centered on alleged undisclosed operational issues. The deadline for shareholders seeking lead plaintiff status is November 18, 2025, underscoring the urgency of this legal action.

A securities fraud class action lawsuit against Stride, Inc. (NYSE: LRN) is moving forward, and a crucial deadline is drawing near. Bernstein Liebhard LLP, the firm leading the action, is inviting investors who purchased shares between October 22, 2024, and October 28, 2025, to assess their legal rights and potential claims.

Investors in Savara Inc. (NASDAQ: SVRA) have been notified by The Schall Law Firm of an ongoing class action lawsuit. The legal claim alleges that Savara violated federal securities law, and it extends an invitation for SVRA shareholders to take the lead in the case.

LifeMD faces a class action lawsuit after disclosing disappointing second-quarter 2025 results and reducing its financial outlook. Shares plummeted 44% from earlier expectations, prompting Hagens Berman to investigate potential securities law violations. The suit covers investors who bought LifeMD securities between May 7 and August 5, 2025.

Investors who purchased American Depositary Shares of Reckitt Benckiser between January 13, 2021, and July 28, 2024, may have the opportunity to lead a securities fraud class action lawsuit. Rosen Law Firm has filed the suit, and the deadline to move the court to serve as lead plaintiff is August 4, 2025.

A father and son have been sentenced for orchestrating a multimillion-dollar fraud involving a small New Jersey deli. The scheme, which inflated the deli’s market value to over $100 million, highlights a sophisticated manipulation of stock prices that deceived investors and institutions alike.

Visa Inc. is under legal scrutiny as investors file a class action lawsuit alleging the company concealed non-compliance with federal antitrust laws, leading to significant financial losses. Affected shareholders have until January 21, 2025, to seek appointment as lead plaintiff in the case led by Levi & Korsinsky, LLP.

Kyverna Therapeutics faces a class action lawsuit alleging the company made false statements and concealed critical information during its February 2024 IPO. Investors who purchased stock may be eligible to join the lawsuit led by Levi & Korsinsky, LLP.